New hope for safer HIV treatment during pregnancy
NCT ID NCT05630638
Summary
This study aims to find the safest and most effective dose of the HIV medication doravirine for pregnant women in South Africa. Researchers will compare the standard HIV treatment to a new combination that includes doravirine, tracking how the drug moves through the body during pregnancy and after birth. The goal is to control the mother's HIV while protecting the baby from infection and ensuring the treatment is safe for both.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Desmond Tutu Health Foundation
RECRUITINGCape Town, South Africa
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.